Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2024 Jul 26;4(7):e0002686. doi: 10.1371/journal.pgph.0002686

Influence of adiposity and sex on SARS-CoV-2 antibody response in vaccinated university students: A cross-sectional ESFUERSO study

Adriana L Perales-Torres 1, Lucia M Perez-Navarro 2, Esperanza M Garcia-Oropesa 1, Alvaro Diaz-Badillo 3,4, Yoscelina Estrella Martinez-Lopez 5, Marisol Rosas 1, Octelina Castillo 1, Laura Ramirez-Quintanilla 1, Jacquelynne Cervantes 6, Edda Sciutto 7, Claudia X Munguia Cisneros 8, Carlos Ramirez-Pfeiffer 1,4, Leonel Vela 9, Beatriz Tapia 9, Juan C Lopez-Alvarenga 4,9,*
Editor: Abram L Wagner10
PMCID: PMC11280215  PMID: 39058698

Abstract

Prior studies have identified various determinants of differential immune responses to COVID-19. This study focused on the Ig-G anti-RBD marker, analyzing its potential correlations with sex, vaccine type, body fat percentage, metabolic risk, perceived stress, and previous COVID-19 exposure. In this study, data (available in S1 Data) were obtained from 108 participants from the ESFUERSO cohort, who completed questionnaires detailing their COVID-19 experiences and stress levels assessed through the SISCO scale. IgG anti-RBD concentrations were quantified using an ELISA assay developed by UNAM. Multiple regression analysis was employed to control for covariates, including sex, age, body fat percentage, body mass index (BMI), and perceived stress. This sample comprised young individuals (average age of 21.4 years), primarily consisting of females (70%), with a substantial proportion reporting a family history of diabetes, hypertension, or obesity. Most students had received the Moderna or Pfizer vaccines, and 91% displayed a positive anti-RBD response. A noteworthy finding was the interaction between body fat percentage and sex. In males, increased adiposity was associated with decreased Ig-G anti-RBD concentration; in females, the response increased. Importantly, this pattern remained consistent regardless of the vaccine received. No significant associations were observed for dietary habits or perceived stress variables. This research reports the impact of sex and body fat percentage on the immune response through Ig-G anti-RBD levels to COVID-19 vaccines. The implications of these findings offer a foundation for educational initiatives and the formulation of preventive policies aimed at mitigating health disparities.

Introduction

Sex differences in metabolism and insulin resistance have been demonstrated in our previous studies with children [13]. Similar findings from various cultural and social contexts support differences in insulin resistance and metabolic-associated liver disease in adults [4]. These differences are partly due to the protective effect of endogenous estrogens on various tissues, including brain, liver, skeletal muscle, adipose tissue, and pancreatic beta cells [5], and other underlying mechanism such as AMPdependent protein kinase (AMPK) activation [6].

Immune responses influenced by sex differences, particularly in LTR8, were reported during the COVID-19 pandemic [7]. Other studies have investigated factors that impact the serum levels of antibodies produced by the COVID-19 vaccine [810]. Age is a critical factor that plays a significant role in determining the immune response. Elderly individuals with obesity and non-prior infection had reduced antibody titers against SARS-CoV-2 spike antigen after CoronaVac vaccine (manufactured in China) compared to non-obese people [11]. Lower antibody response after receiving two doses of the Pfizer vaccine has also been linked to central obesity (correlation of r = -0.3), the presence of hypertension, and smoking habits, with no notable differences by gender [12].

During the pandemic, it became evident that metabolic imbalances associated with obesity could increase the severity of COVID-19 and the risk of mortality [13, 14]. Diet can induce metabolic and immune impairments, which may vary based on sex, as shown in animal studies [15, 16]. Interestingly, losing weight has been shown to improve the adaptive immune response, particularly an increase in INF-g2 levels following the administration of two doses of mRNA vaccine [17].

Sex and body weight interaction can also result in varying immune responses. For individuals with a BMI >40 kg/m2, there were no discernible differences in IgG antibody levels between the sexes [18]. In contrast, those with normal weight showed higher levels among males [19]. Physical activity and migration have influenced immunological markers and health outcomes [20, 21]. Psychological stress is another recognized variable affecting the immune response [22, 23] Early-life adversity, affecting 39% of the world’s population, has been associated with neuroinflammation and increased levels of soluble tumor necrosis factor in animal studies [24]. Diet and stress can serve as effect modifiers of biological variables like sex and adiposity.

The present study focused on a nested sample of students from the ESFUERSO (EStudio de la Frontera Urbana para las EnfeRmedades y factores aSociados a la Obesidad) program. These students experienced the impact of the COVID-19 pandemic, which forced them into home confinement and led to changes in their habits.

The development of mRNA vaccines has been a long journey, beginning with cell cultures and laboratory animal testing, followed by industry investment and veterinary applications, ultimately leading to human vaccination in 2020. These efforts have been ongoing for three decades [25].

This study aimed to analyze the mathematical function of the immune response to the receptor-binding domain (RBD), a protective epitope found in the S protein [26], by examining the Ig-G response among young students from Mexico living near the US-Mexico border. The analyzed factors included sex, body fat, psychological stress, and food consumption (Fig 1A).

Fig 1.

Fig 1

The top panel (A) presents the initial hypothesis, in which we expected sex and body fat to affect the immune response to COVID-19 vaccination, with psychological factors and food ingestion acting as effect modifiers. The bottom panel (B) concludes that the immune response differed between males (trend to negative association) and females (trend to positive association), and the effect modifiers did not play a role in this study.

Methods

Study sample

In 2018, the ESFUERSO cohort study was initiated, focusing on 500 first-year students from two universities in Reynosa, Tamaulipas. Characteristics of this sample were described elsewhere [27]. In summary, 70% of the participants were considered to have metabolic risk if they had a BMI > 30 or a family history of obesity, diabetes, or hypertension.

For the current study, we intended a proportional sample with 70% of students with metabolic risk who accepted to participate and could attend near the university facilities. Due to the pandemic, not all students could attend, and only a subset of 116 students were contacted between September 1st and October 31st, 2021. During this period, we obtained signed informed consent (see Ethics Statement below for details), conducted questionnaire surveys, collected anthropometric measurements, and collected blood samples from 108 students in compliance with the COVID-19 protocol managed by the universities. Eight students initially agreed to participate but did not complete the surveys or clinical measurements.

Measures

The questionnaires and methods used in the ESFUERSO study have been described elsewhere [27]. Briefly, the questionnaires collected information on family metabolic risk, anxiety, depression, and uncertainty. The Cronbach α coefficient from each question ranged from 0.72–0.96. The test-retest for agreement in categorical variables was a kappa coefficient between 0.5–0.91 and an intraclass correlation coefficient between 0.73–0.96 in continuous variables. The stress during the pandemic was evaluated with SISCO (Modelo SIStémico COgnoscitivista para el estudio del estrés académico), to assess distress, uncertainty, lack of sleep, sadness, and anxiety. The SISCO was validated in Mexico and other Latin American countries with a Cronbach α coefficient of 0.9 with high homogeneity [28]. The food ingestion scores were calculated using a semi-quantitative questionnaire about 42 selected regional foods. The weighted kappa was greater than 0.6 for all items in a reliability study [29]. All the questionnaires were administered electronically, with students completing them on their cell phones. This approach ensured efficient data collection and minimized the need for physical paperwork or in-person administration.

Weight, height, and acanthosis nigricans grade [30] were assessed and registered at the universities by a standardized nutritionist [27]. The body fat percentage was measured by bioelectrical impedance using a body composition analyzer (Tanita TBF-300A). Blood samples were obtained between 7 to 9 am (after an overnight fasting period) for the measurement of serum concentration of Ig-G anti-RBD by indirect ELISA [26]. The samples underwent centrifugation following collection, and four aliquots were stored at -20 C. These aliquots were transported to Mexico City in cold conditions in November 2021 for antibody analysis. The effective neutralizing concentration of anti-RBD IgG was assessed, and this variable was analyzed in both continuous and dichotomous dimensions. A threshold of 1.0 for the anti-RBD IgG ratio was established to differentiate between effective and non-effective neutralization.

Statistical analysis

Descriptive statistics included percentages for categorical variables and means with standard deviations or medians and interquartile range (Q1, Q3) for continuous variables. Inferential statistics utilized regression analysis to evaluate the relation in the SISCO questionnaire scores; the food ingestion scores with 42 selected regional foods were reduced to 12 factors (KMO = 0.64 supporting suitability analysis for principal components and varimax rotation) [29]. Locally weighted regression (lowess) was performed to assess nonlinear relationships. The analysis used antibody concentration as the dependent variable, adjusting for sex, age, metabolic risk, body fat percentage, and BMI. Multiplicative interactions for covariates were analyzed. The variance inflation factor (VIF) was calculated to evaluate multicollinearity in variables used in linear models without interactions [31]. Multicollinearity occurs when two or more independent variables in a regression model are highly correlated, making accurately estimating each variable’s effect on the dependent variable difficult. The VIF quantifies the extent to which multicollinearity increases an estimated regression coefficient’s variance (i.e., the uncertainty or variability) [32, 33].

We evaluated three models (presented in Table 2) covering sex, body fat, psychological variables, and food ingestion; some included an interaction term for body fat percentage and sex. The models included first—to third-grade polynomial multiple regression, and the goodness of fit was assessed using a squared error calculation. The best goodness of fit for data was achieved with polynomial multiple regression using a sample of 108 students with complete data. All analyses were performed with Stata V18.0 (StataCorp, College Station, TX).

Table 2. Statistical models test the hypothesis.

Model 1. Effect of psychological variables Model 2. Effect of food preferences Model 3. Interaction between body fat and sex
Sex (Male) 0.87 (-0.07, 1.81) 1.0 (0.05, 1.9) -0.66 (-2.79, 1.46)
Fat percentage (%) 0.02 (0.002, 0.037) 0.02 (0.004, 0.038) -0.23 (-0.41, -0.04)
Sex*Fat% (Male) -0.03 (-0.06, 0.005) -0.03 (-0.06, -0.001) 0.16 (-0.15, 0.48)
Sex*Fat%^2 (Female) 0.01 (0.002, 0.017)***
Sex*Fat%^2 (Male) 0.004 (-0.01, 0.02)
Sex*Fat%^3 (Female) -0.001 (-0.0001, -0.00002)
Sex*Fat%^3 (Male) -0.0001 (-0.0003, 0.0001)
Distress -0.05 (-0.20, 0.10)
Uncertainty 0.11 (-0.07, 0.28)
Lack of sleep -0.06 (-0.18, 0.07)
Sadness 0.01 (-0.13, 0.16)
Anxiety 0.01 (-0.14, 0.16)
Twelve factors of food -0.12 (-0.27, 0.03) to 0.10 (-0.04, 0.25)
Adj R^2 0.001 0.04 0.08
Root MSE 0.76 0.75 0.74

The regression coefficients (95%CI) are presented in a summary of the regression models analyzed. To ensure the integrity of our analysis, we addressed potential collinearity issues (detailed in the text) and limited our examination to relationships among variables based on established clinical criteria. The table includes two key statistical measures for each model: the Adjusted R^2, representing the proportion of variance explained by the model (adjusted for the number of predictors), Mean Square Error to quantify the standard deviation of the residuals, and measuring the model’s accuracy. Adj R^2: Adjusted coefficient of determination. Root MSE: Root of Mean Square Error.

†p<0.10

‡p<0.05

***p<0.01.

Ethics statement

The protocol and informed consent were approved by the Comite de Etica Institucional de la Unidad Academica Multidisciplinaria Reynosa-Aztlan (CEI-UAMRA) number registration CEI-UAMRA 005/2019/CEI under Health normativity (NOM-012-SSA-3-212). The informed consent detailed the risks and benefits and ensured no cost to the participants, who had the right to withdraw from the project without any questions. All participants signed the approved informed consent. The present report followed the STROBE recommendations for cross-sectional studies [34].

Results

A total of 108 students in the ESFUERSO cohort were enrolled during the 3rd year of the cohort follow-up in Reynosa. The participants had a mean age of 21.4 (SD 1.0) years, an average BMI of 27.9 (SD 6.2), and gender distribution of 69% (75 out of 108) female students. The presence of T2D, hypertension, obesity, or a combination of the conditions was identified in 70% of the students. Notably, there were no discernible differences between universities on metabolic risk, anthropometry, sex, and commercial brand of vaccine or the presence of adequate antibody levels (Table 1). Only 3 (3%) of the students from the private university had no COVID-19 vaccination at the time of the study, and they also belonged to the metabolic risk group (Pearson standardized distance >3.0). From vaccinated students, 97 (90%) were immunized with Moderna or Pfizer, and only 8 (7%) with other vaccines (Johnson & Johnson n = 1, Cansino n = 6, Sinovac n = 1). The prevalence of positive anti-RBD was 91%, with similar values by sex (Table 1).

Table 1. Descriptive statistics of general variables by sex.

Variable Female students (n = 75) Male students (n = 33)
Age (years)* 21.4 ±1.1 21.4 ±0.9
BMI (kg/m2) * 27.7 ± 6.1 28.4 ± 6.3
Body fat (%)* 33.04 ± 10.45 24.2 ± 10.34
Waist circumference (cm) * 83.3 ±13.2 91.9 ±13.7
Neck circumference (cm) * 34.4 ±3.2 40.4 ±10.6
Systolic blood pressure (mmHg) * 113 ±9 120.8 ±18.7
Diastolic blood pressure (mmHg) * 77 ±7 81.1 ±92.9
Positive RBD (%) 66 (88%) 31 (94%)
Anguish** 3 (2, 5) 3 (1, 4)
Uncertainty** 3 (2, 4) 2 (1, 4)
Lack of sleep** 4 (2, 5) 2 (1, 3)
Sadness** 3 (3, 5) 2 (1, 3.5)
Anxiety** 4 (3, 5) 3 (1.5, 4)
Acanthosis nigricans** 0 (0, 2) 1 (0, 2)

* Continuous variables presented mean and standard deviation.

**Ordinal variables present the median along the first and third quartile (Q1, Q3).

The multicollinearity analysis showed BMI and fat percentage had VIF = 4.8 and 1/VIF = 0.02. This suggested a moderate level of collinearity, so we analyzed separating both variables to maintain a clear interpretation of the regression coefficients. The anthropometric analysis showed the body fat percentage had the lowest BIC (BIC = 259.9) compared with BMI (BIC = 261.2) and waist circumference (BIC = 264.4). Table 2 shows the results of body fat percentage with sex interaction. The body fat percentage interaction with sex was statistically significant, supporting the serum concentration of anti-RBD decreased as adiposity increased in men (p = 0.034 for a second-grade term). Still, anti-RBD increased with adiposity in women (p = 0.01, p = 0.015 for second and third-grade terms) (Fig 2). The interaction remained despite the vaccine types. The adjusted model minimized the mean squared error (Root MSE = 0.74) and adjusted coefficient of determination (R^2 = 0.08), compared with other models (Fig 3 and Table 2). The residuals adjusted to a normal distribution (Shapiro-Wilkins p = 0.136).

Fig 2. Sex differences in neutralizing anti-RBD IgG ratios as a function of body fat percentage.

Fig 2

This figure illustrates the relationship between neutralizing anti-RBD (Receptor Binding Domain) IgG ratios and body fat percentage among university students, using the Lowess (Locally Weighted Regression) smoothing technique to highlight trends. Females and males are distinguished by diamonds and crosses, respectively, with the Lowess curve for females presented as a continuous line and for males as a dashed line.

Fig 3. Polynomial regression analysis of anti-RBD IgG ratios predicted by body fat percentage.

Fig 3

This figure shows the relationship between anti-RBD IgG ratios and body fat percentage for university students, modeled with a polynomial regression to capture the nuances of this relationship. A 3rd-degree polynomial regression is applied for females and a 2nd-degree polynomial for males, reflecting the differential complexity of their responses. Females are depicted with white circles, and males with black circles.

No differences due to metabolic risk factors or effective antibody concentration were found for food consumption and psychological variables (distress, uncertainty, lack of sleep, sadness, and anxiety) presented in Table 2.

Discussion

Based on the results of our study, it appears that the neutralizing anti-RBD response to the COVID-19 vaccine is influenced by a multiplicative interaction of sex and body fat percentage. Specifically, females tend to have increased responses, while males tend to have decreased responses (Fig 3). Stress scores do not appear to have significant effects (Fig 1B).

This observation aligns with existing research on sex-based differences in immune responses. For instance, a study involving the Cameron County Hispanic Cohort, which included 624 participants with a mean age of 50 (SD 14) years, has previously reported sex-specific variations in adipokines and carotid intima-media thickness [35]. The present study extends these findings to a younger cohort, specifically individuals in the final stages of adolescence residing near the U.S.-Mexico border. This highlights the relevance of considering age and geographic location when examining immune response differences between sexes.

Another study conducted in Mexico on 980 adult participants with a median age of 50 (Q1: 36, Q3: 54) who had obesity before mass vaccination sheds light on this [36]. The authors identified independent factors associated with SARS-Cov-2 infection in a symptomatic group. Their findings revealed higher levels of anti-S1/2 antibodies in individuals with advanced age, type 2 diabetes, hypertension, and a positive correlation with BMI [36]. Furthermore, women exhibited higher levels of anti-RBD IgG antibodies compared to men. The authors emphasized the vulnerability of individuals with underlying health conditions, including obesity, to SARS-CoV-2 infection, a concern that is particularly pronounced in older populations. While our study focuses on a younger cohort, providing valuable insights into this demographic group.

Other populations have reported similar findings. Yamamoto et al. [37], reported sex–associated differences in the relationship between body mass index and SARS-CoV-2 antibody titers following the BNT162b2 vaccine in a study of 2,435 healthcare workers in Japan. A meta-analysis examining antibody responses to COVID-19 vaccinations also indicated a significant association between obesity and reduced antibody response [38]. Nevertheless, the considerable heterogeneity (88%) observed across studies suggests that biological factors, including sex, age, and body fat, play a pivotal role in these outcomes.

Tailoring vaccination plans based on an individual’s characteristics may enhance vaccine effectiveness. Addressing sex-specific and body fat-related factors in public health interventions can reduce infection rates. Considering the social determinants in the U.S.-Mexico border region, the information provided in this study can help in programs to educate individuals about their susceptibility to infections.

One strength of the study was that the interaction terms captured the combined effect of how body fat percentage and sex jointly influence the antibody response to a vaccine. Another was evaluating multiple models, including first—to third-degree polynomial regressions (non-linear models), which allowed for a comprehensive data analysis. This approach helped determine the best model that fits the data, ensuring robust and reliable results.

While the present study yields valuable insights, it is important to acknowledge several potential limitations. Variations in immune responses across different age groups, the influence of genetic factors, and the impact of social determinants can introduce complexities that our study may not fully capture. Moreover, it’s essential to recognize that the study’s cross-sectional design allows for identifying associations but does not establish causality. These considerations emphasize the need for caution in generalizing the findings and highlight avenues for further research.

Conclusion

This study provides novel insights into the response of anti-RBD IgG antibodies to vaccination in a young cohort. The findings reveal a complex relationship between sex and body fat percentage, depicted by a third-degree polynomial curve (Fig 3). This emphasizes the intricate interplay between body fat and the immune response to vaccines and accentuates the importance of considering sex-specific factors, especially among younger individuals. The complexity of these interactions supports the need for further studies that explicitly include the analysis of sex and fat percentage. Comprehensive knowledge of distinct characteristics and immunological responses helps to understand social and biological dynamics for tailoring vaccination strategies, optimizing public health interventions, and reducing health disparities.

Supporting information

S1 Checklist. Inclusivity in global research.

(DOCX)

pgph.0002686.s001.docx (66.1KB, docx)
S1 Data. Dataset.

(XLSX)

pgph.0002686.s002.xlsx (33.3KB, xlsx)

Acknowledgments

Preliminary results of this study were presented and recognized as the best oral clinical presentation at the UTRGV School of Medicine’s 5 th Annual Research Symposium, 2021, Mission, TX. The study was supported by a grant to ALPT from the Convocatoria 2021–01: Impulso a la Investigación Científica y de Tecnología Aplicada, COTACyT grant number: COTACYT-2021-01-23. The authors acknowledge the generous support the Universidad Mexico Americana del Norte, the Universidad Autónoma de Tamaulipas for supporting ESFUERSO sharing spaces, personnel, laboratory facilities, and the enthusiastic participation of alumni, staff, and faculty. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Data Availability

The dataset is available at https://scholarworks.utrgv.edu/cgi/ir_submit.cgi?context=som_pub.

Funding Statement

This study was supported by a grant for ALPT from COTACYT-2021-01-23, Mexico. The funders had no role in study design, data collection and analysis, decision to publish, or preparationof the manuscript.

References

  • 1.Garibay-Nieto N, Hernandez-Moran BA, Villanueva-Ortega E, Garces-Hernandez MJ, Pedraza-Escudero K, Arroyo-Valerio A, et al. Comparison of Carotid Intima-Media Thickness in Children and Adults With and Without Obesity: A Hysteresis Model. Endocr Pract. 2022;28(3):315–20. Epub 20211208. doi: 10.1016/j.eprac.2021.12.002 . [DOI] [PubMed] [Google Scholar]
  • 2.Garces-Hernandez MJ, Pedraza-Escudero K, Garibay-Nieto N, Hernandez-Ruiz J, Prieto-Chavez JL, Arriaga-Pizano LA, et al. The CCR2(+) Monocyte Subsets Increase in Obese Boys but Not Girls with Abnormally High Carotid Intima-Media Thickness: A Pilot Study. J Cardiovasc Dev Dis. 2022;9(10). Epub 20220929. doi: 10.3390/jcdd9100330 ; PubMed Central PMCID: PMC9604509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Villanueva-Ortega E, Garces-Hernandez MJ, Herrera-Rosas A, Lopez-Alvarenga JC, Laresgoiti-Servitje E, Escobedo G, et al. Gender-specific differences in clinical and metabolic variables associated with NAFLD in a Mexican pediatric population. Ann Hepatol. 2019;18(5):693–700. Epub 20190522. doi: 10.1016/j.aohep.2019.04.012 . [DOI] [PubMed] [Google Scholar]
  • 4.Wei Y, Liu J, Wang G, Wang Y. Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults. Biol Sex Differ. 2023;14(1):69. Epub 20231009. doi: 10.1186/s13293-023-00549-0 ; PubMed Central PMCID: PMC10561490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63(3):453–61. Epub 20191121. doi: 10.1007/s00125-019-05040-3 ; PubMed Central PMCID: PMC6997275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kvandova M, Puzserova A, Balis P. Sexual Dimorphism in Cardiometabolic Diseases: The Role of AMPK. Int J Mol Sci. 2023;24(15). Epub 20230726. doi: 10.3390/ijms241511986 ; PubMed Central PMCID: PMC10418890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Del Carmen Camacho-Rea M, Martinez-Gomez LE, Martinez-Armenta C, Martinez-Nava GA, Ortega-Pena S, Olea-Torres J, et al. Association of TLR8 Variants in Sex-Based Clinical Differences in Patients with COVID-19. Biochem Genet. 2024. Epub 20240530. doi: 10.1007/s10528-024-10839-w . [DOI] [PubMed] [Google Scholar]
  • 8.Cheng ZJ, Xue M, Zheng P, Lyu J, Zhan Z, Hu H, et al. Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines (Basel). 2021;9(8). Epub 20210805. doi: 10.3390/vaccines9080869 ; PubMed Central PMCID: PMC8402513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kodde C, Tafelski S, Balamitsa E, Nachtigall I, Bonsignore M. Factors Influencing Antibody Response to SARS-CoV-2 Vaccination. Vaccines (Basel). 2023;11(2). Epub 20230215. doi: 10.3390/vaccines11020451 ; PubMed Central PMCID: PMC9967627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nam SY, Jeon SW, Lee HS, Lim HJ, Lee DW, Yoo SS. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Netw Open. 2022;5(5):e2212996. Epub 20220502. doi: 10.1001/jamanetworkopen.2022.12996 ; PubMed Central PMCID: PMC9121186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kara Z, Akcin R, Demir AN, Dinc HO, Kocazeybek B, Yumuk VD. Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity. Obes Facts. 2023;16(4):374–80. Epub 20230525. doi: 10.1159/000530315 ; PubMed Central PMCID: PMC10443995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465. Epub 20210511. doi: 10.1002/dmrr.3465 ; PubMed Central PMCID: PMC8209952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fishkin T, Goldberg MD, Frishman WH. Review of the Metabolic Risk Factors for Increased Severity of Coronavirus Disease-2019. Cardiol Rev. 2021;29(6):292–5. doi: 10.1097/CRD.0000000000000408 ; PubMed Central PMCID: PMC8489576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9(11):786–98. Epub 20211004. doi: 10.1016/S2213-8587(21)00244-8 ; PubMed Central PMCID: PMC8489878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rodrigues MES, Bolen ML, Blackmer-Raynolds L, Schwartz N, Chang J, Tansey MG, et al. Diet-induced metabolic and immune impairments are sex-specifically modulated by soluble TNF signaling in the 5xFAD mouse model of Alzheimer’s disease. Neurobiol Dis. 2024;196:106511. Epub 20240424. doi: 10.1016/j.nbd.2024.106511 . [DOI] [PubMed] [Google Scholar]
  • 16.Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, et al. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis. 2014;67:79–87. Epub 20140329. doi: 10.1016/j.nbd.2014.03.011 ; PubMed Central PMCID: PMC4083060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Watanabe M, Balena A, Masi D, Tozzi R, Risi R, Caputi A, et al. Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine. Vaccines (Basel). 2022;10(1). Epub 20220105. doi: 10.3390/vaccines10010079 ; PubMed Central PMCID: PMC8780354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239–49. Epub 20181213. doi: 10.1007/s00281-018-0726-5 ; PubMed Central PMCID: PMC6373179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kara Z, Akcin R, Demir AN, Dinc HO, Taskin HE, Kocazeybek B, et al. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obes Surg. 2022;32(9):2987–93. Epub 20220708. doi: 10.1007/s11695-022-06181-y ; PubMed Central PMCID: PMC9263798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gonzalez-Barranco J, Lopez-Alvarenga JC, Roiz-Simancas M, Bravo-Garcia AL, Fanghanel-Salmon G, Laviada Arrigunaga E, et al. [Migration from a rural zone to an urban one is associated with android distribution of body fat in obese women]. Rev Invest Clin. 2001;53(2):129–35. . [PubMed] [Google Scholar]
  • 21.Landeros-Olvera E, Lopez-Alvarenga JC, Nava-Gonzalez EJ, Gallegos-Cabriales E, Lavalle-Gonzalez F, Bastarrachea RA, et al. [Cardiovascular exercise on obese women: effects on adiponectine, leptine, and tumour necrosis factor-alpha]. Arch Cardiol Mex. 2014;84(3):177–82. Epub 20140801. doi: 10.1016/j.acmx.2013.11.007 . [DOI] [PubMed] [Google Scholar]
  • 22.Madison AA, Shrout MR, Renna ME, Kiecolt-Glaser JK. Psychological and Behavioral Predictors of Vaccine Efficacy: Considerations for COVID-19. Perspect Psychol Sci. 2021;16(2):191–203. Epub 20210127. doi: 10.1177/1745691621989243 ; PubMed Central PMCID: PMC7841255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dragos D, Tanasescu MD. The effect of stress on the defense systems. J Med Life. 2010;3(1):10–8. ; PubMed Central PMCID: PMC3019042. [PMC free article] [PubMed] [Google Scholar]
  • 24.Eidson LN, deSousa Rodrigues ME, Johnson MA, Barnum CJ, Duke BJ, Yang Y, et al. Chronic psychological stress during adolescence induces sex-dependent adulthood inflammation, increased adiposity, and abnormal behaviors that are ameliorated by selective inhibition of soluble tumor necrosis factor with XPro1595. Brain Behav Immun. 2019;81:305–16. Epub 20190625. doi: 10.1016/j.bbi.2019.06.027 ; PubMed Central PMCID: PMC8597195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318–24. doi: 10.1038/d41586-021-02483-w . [DOI] [PubMed] [Google Scholar]
  • 26.Ayon-Nunez DA, Cervantes-Torres J, Cabello-Gutierrez C, Rosales-Mendoza S, Rios-Valencia D, Huerta L, et al. An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population. Diagnostics (Basel). 2022;12(7). Epub 20220705. doi: 10.3390/diagnostics12071629 ; PubMed Central PMCID: PMC9324632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Garcia-Oropesa EM, Perales-Torres AL, Martinez-Lopez YE, Munguia-Cisneros CX, Nava-Gonzalez EJ, Perez-Navarro M, et al. Effect of Insulin Resistance on Abdominal Obesity, Liver Fat Infiltration, and Body Mass Index in Youngsters. Arch Med Res. 2023;54(7):102873. Epub 20230901. doi: 10.1016/j.arcmed.2023.102873 . [DOI] [PubMed] [Google Scholar]
  • 28.Barraza-Macias A. El estrés de la pandemia (COVID 19) en población Mexicana.: Centro de Estudios Clinica e Investigacion Psicoanalitica S.C.; 2020. [Google Scholar]
  • 29.Lopez-Alvarenga JC, Vazquez-Velazquez V, Bolado-Garcia VE, Gonzalez-Barranco J, Castaneda-Lopez J, Robles L, et al. [Parental influence in children’s food preferences. The ESFUERSO study in two primary schools with different socioeconomic gradients]. Gac Med Mex. 2007;143(6):463–9. . [PubMed] [Google Scholar]
  • 30.Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care. 1999;22(10):1655–9. doi: 10.2337/diacare.22.10.1655 . [DOI] [PubMed] [Google Scholar]
  • 31.Chatterjee S, Yilmaz M. A Review of Regression Diagnostics for Behavioral Research. Applied Psychological Measurement. 1992;16(3):209–27. doi: 10.1177/014662169201600301 [DOI] [Google Scholar]
  • 32.Marquardt DW. Generalized Inverses, Ridge Regression, Biased Linear Estimation, and Nonlinear Estimation. Technometrics. 1970;12(3):591–612. doi: 10.2307/1267205 [DOI] [Google Scholar]
  • 33.Detecting and Assessing Collinearity. Regression Diagnostics1980. p. 85–191.
  • 34.Network. E. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. 2023 [updated March 6, 2023.October 25, 2023.]. Available from: https://www.equator-network.org/reporting-guidelines/strobe/].
  • 35.Kim D, Memili A, Chen HH, Highland HM, Polikowsky HG, Anwar MY, et al. Sex-specific associations between adipokine profiles and carotid-intima media thickness in the Cameron County Hispanic Cohort (CCHC). Cardiovasc Diabetol. 2023;22(1):231. Epub 20230831. doi: 10.1186/s12933-023-01968-4 ; PubMed Central PMCID: PMC10472619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Montes-Herrera D, Munoz-Medina JE, Fernandes-Matano L, Salas-Lais AG, Hernandez-Cueto MLA, Santacruz-Tinoco CE, et al. Association of Obesity with SARS-CoV-2 and Its Relationship with the Humoral Response Prior to Vaccination in the State of Mexico: A Cross-Sectional Study. Diagnostics (Basel). 2023;13(16). Epub 20230809. doi: 10.3390/diagnostics13162630 ; PubMed Central PMCID: PMC10453006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yamamoto S, Mizoue T, Tanaka A, Oshiro Y, Inamura N, Konishi M, et al. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine. Obesity (Silver Spring). 2022;30(5):999–1003. Epub 20220412. doi: 10.1002/oby.23417 ; PubMed Central PMCID: PMC9088326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ou X, Jiang J, Lin B, Liu Q, Lin W, Chen G, et al. Antibody responses to COVID-19 vaccination in people with obesity: A systematic review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1):e13078. Epub 20221219. doi: 10.1111/irv.13078 ; PubMed Central PMCID: PMC9835425. [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002686.r001

Decision Letter 0

Abram L Wagner

30 Jan 2024

PGPH-D-23-02208

Adiposity and Sex Influence on SARS-CoV-2 Antibody Response in University Students. An ESFUERSO cross-sectional study.

PLOS Global Public Health

Dear Dr. Lopez-Alvarenga,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 15 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Abram L. Wagner, PhD, MPH

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/globalpublichealth/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

Reviewer #4: Yes

Reviewer #5: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: I don't know

Reviewer #4: Yes

Reviewer #5: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study explored an important area of significant public health interest. It adds important findings to the already existing information and opens a window for more research. The methodology is explicit and supported by rigorous statistical analysis. Ethical issues have been taken in to consideration and the language used is explicit. The main findings are well presented. Limitations of the study have been highlighted for appropriate interpretation of results.

Reviewer #2: Manuscript is good, clear and recommend to publish with minor revision. First of all, there is need to describe more preciously figure 1 and figure 2, or present those figures in tables.

All other section are clear.

Reviewer #3: The major strengths of the paper are the collection of anthropometric and lab data, and the relevance of the topic by both disease burden and underserved population, as well as to current policy debates. The major weaknesses of the paper are mostly related to drafting. The paper requires a more substantive background section to set up the literature that appears in the otherwise well-done discussion section and to motivate the study. The paper also requires a lot more detail to describe the methods so that they can be assessed by reviewers and reproduced by others.

I think the paper is potentially an important contribution to the field but requires additional writing particularly in the background and methods sections, and at least one additional table.

My main comments are below, followed by a few line-by-line substantive comments, and then some minor copyediting comments.

Main comments:

The background section is a little sparse. At the moment, I’m a little unclear as to how this study was motivated. It’s also not clear what your main independent variable was before you ran the analysis. Was it the SISCO measures? Or was this an exploratory study to see what factors account for immune response? If so, it would be helpful to state that.

How and why did you choose the factors to analyze? You’ve provided some justification for assigned sex at birth and adiposity in the background, but not for other covariates or for your main outcome. Though it’s not clear to me that you’re actually building models for sex and adiposity that would adjust for the right confounders. Does the literature point the way towards any covariates that would be important to include in measuring the effects of adiposity and sex on immune response? Is there literature on other vaccines and interactions between adiposity and sex?

Much more information is needed in the methods section on how all of your measures were operationalized. E.g. you note a “metabolic risk group” in 173-174, but didn’t describe in methods how you created this group. How was vaccination assessed? Was it self-report, administrative records, medical records, something else? How were body fat percentage, weight circumference, neck circumference, and blood pressure assessed? It’s important to describe for all those measures, but particularly for body fat percentage as it’s central to your analysis.

Every model that you ran should be described in the methods section, and ideally there should be a table with your results (including the non-significant ones). The way I understand it, you ran a separate model for each of the 6 factors listed at the bottom of Table 1 plus another for food consumption, though that number may be a lot more since it appears as if you tested different models for interactions separately. Or was it just one model with all of the factors loaded in? Describing it in the methods section would greatly clarify how many models for the reader, which is important because depending on how many models you ran, there starts to become an increased risk that that many tests of significance may result in something statistically significant just due to the sheer volume of tests.

It’s still not clear to me which model you ran includes the interaction term for fat percentage and sex.

Table 1: I see food consumption as something that was measured and analyzed (195). How that was measured and operationalized should be described in methods, and should be included in table 1.

The dataset was not available at the provided link (it may have required a UT:RGV login)

There’s not enough information in methods currently to assess whether the results back up the discussion points.

216-248 is well-written and highly relevant. These studies should have been mentioned in the background to establish the literature and motivate the current study.

Line-by-line comments:

113-114: Do you mean the parents of the students? Or the initial cohort?

114: Why were the students contacted due to the pandemic? Why was it this subset in particular (random, administrative reasons, etc.?) and not the entire cohort?

138: might be useful to include the distance and method of transport and/or summarize the sample preservation procedure during transport

161/165: Is it 114 students or 108?

168-169: Unclear what you mean by “significantly” here, was it statistically significant? Or did they meet some pre-defined threshold?

167: How was sex assignment determined? Was it self-report or administrative data?

184: Describe how to interpret this VIF for readers who may be unfamiliar with VIF.

186: Given the limitations of this study, causality can’t be established here, so be cautious of using “explaining” to describe this relationship.

Minor copyediting comments:

58: unsure what “adeptly” is referring to here

100: Needs a citation

151: needs to be a sentence

151-162: Could use some minor copyediting

167: “female students” rather than "females"

Reviewer #4: General comments:

Well articulated molecular level understudy of vaccine, especially COVID-19 vaccines which was globally used in curbing the pandemic.

This study underscores multiple factors that could affect vaccine take, and can be extrapolated to other vaccines especially childhood RI vaccines looking at familial, environmental, dietary and other domains for further development of vaccines.

Studying younger age-groups as in this study helps to target larger percentage of the population pyramid and hence large vulnerable groups that are our future technocrats and leaders, therefore helping humanity in essence.

Suggestions:

Title:

Adiposity and sex influence in vaccinated university students on SARS COV-2 Antibody response: An ESFUERSO cross- sectional study.

Key words:

COVID-19 vaccines; sex; adiposity; immune response; regression analysis; anti-RBD

Abstract: ok

Introduction: ok

Methods:

Line 137-these aliquots were subsequently

Statistical analysis:

Line 151- with percentages for count variables

Results:

Line 169-conditions were identified

Line171- only 3(3%) of the students

Line 189- the interaction remained in spite of the vaccine types.

Discussion: ok

References:

Other COVID-19 vaccine studies in younger age groups globally could be relevant?.....add a few please

Reviewer #5: Title:

Adiposity and Sex Influence on SARS-CoV-2 Antibody Response in University Students. An ESFUERSO cross-sectional study.

Abstract

Line 66: “… this trend was …” => which trend?

Introduction

Line 76: Insert references after the word conducted.

Line 80: Why reference comes after a dot (.)? => .(1) should read (1). Please correct this in the whole document.

Line 87: “BMI > 40 kg/m2” should read “BMI > 40 kg/m2”.

Line 90: If ESFUERSO is an abbreviation, can it be explained in full here?

Line 88: Insert reference after the word responses.

Lines 91-92: “… which recruited first-year college students living in Reynosa prior the

COVID-19 pandemic in 2018”. => this sentence should be part of methods section, not introduction.

Lines 92-99: “This group of students reported … psychological stress”. This paragraph looks like results rather than introduction. Can this be clarified?

Lines 99-100: “Vaccination 99 efforts began in 2021, employing novel mRNA vaccine used in veterinary science for three decades”. => Did authors do vaccination as part of this study (method)? If not, then this sentence needs reference if it comes from the literature.

Lines 102-103: “The aim of this study was …” => start this as a new paragraph.

Lines 105-106: “The study provides insights in the immune response and the potential implications in the context of COVID-19”. => This sentence should come later in the results or discussion.

Comment for the introduction: This section of the manuscript is too short, less than one page is not sufficient. There is no clear rational of the study described here. Authors need to screen further literature to make this section rich and explain why this study is important and/or needed.

Methods

Line 111: Better to avoid confusion: is the ESFUERSO study the one that is being published in this manuscript or different? How sample size was calculated? 500? 116? 108? Better to stick on sample size for your manuscript and explain how you got this figure. Did the authors check the power for this sample size to be representative of the studied population? A subset of 116, was it for what (survey, blood collection or both)?

Line 110: Based on the content of this paragraph, this title should be: Study sample, design, and data collection. Please describe the study design for your research (it seems to be a quantitative clinical study and comparative, I guess). Did the authors respect GCP procedures? Were there SOP and training of study staff done? What was done for the

Attachment

Submitted filename: Peer review comments from Mateus_Art5.docx

pgph.0002686.s003.docx (21.9KB, docx)
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002686.r003

Decision Letter 1

Abram L Wagner

10 May 2024

PGPH-D-23-02208R1

Influence of Adiposity and Sex on SARS-CoV-2 Antibody Response in Vaccinated University Students: A Cross-Sectional ESFUERSO study .

PLOS Global Public Health

Dear Dr. Lopez-Alvarenga,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

You made good progress in responding to previous reviewer comments. Reviewer 3 still has some outstanding comments. A lot of this is just to make the organization of your paper a bit tighter. If there can be a clearer thread that is balanced on your study aims (last paragraph of intro) - with the intro building up to it, and the methods explaining what you do as a result, I think this would be helpful.

Please submit your revised manuscript by Jun 24 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Abram L. Wagner, PhD, MPH

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

Reviewer #5: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #2: Yes

Reviewer #3: Partly

Reviewer #5: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: After revision article is good and clearly described.

Reviewer #3: Re-Review for Perales-Torres et al.

Introduction

The introduction is improved. However, the whole paper would benefit from a conceptual diagram (even a simple one), as well as an objective statement, that connects some of the concepts in the introduction (that you added this round) to your study methods. In your response to reviewer 5 you mentioned that you kept the introduction short to keep things concise: I don’t think it’s about literal length per se, so much as you still have not motivated the study yet in this round of revisions. Right now, thinking from the perspective of a naïve reader, it’s not clear why you selected the methods you did because the research question and how you intend to answer that research question are still not clear. E.g. It is not clear to me why you evaluate *these seven models*? Why does a reader want to look at stress as measured by SISCO here? Why should a reader want to know about the effects of your independent variables on RBD? That’s why it’s not clear from the text whether this paper is exploratory analysis—something I mentioned last round—while your response to reviewers makes it clear that you do have specific hypotheses (and which you begin to hint at this round in the introduction). If you have hypotheses, *make them explicit* to the reader in an objectives statement. A conceptual diagram, with the components explained and referenced in the text of the Introduction, will also help you make explicit what exactly you’re operationalizing using your measures and why. Otherwise, there is not enough information for reviewers or readers to assess the *internal validity* of your study. Your response to reviewers (both to me and to reviewer 5) explains this relatively well, that level of explicit explanation should be in the paper itself.

89-90: needs a reference (unless it’s meant to refer to citation (7), in which case the sentence should be edited for clarity).

99: needs something at the beginning of the sentence to make clear that you’re referring to widespread vaccination efforts, rather than an activity that your study carried out. E.g. “Country-wide vaccination efforts…”

104: needs a citation for the protective epitope. And needs more background explanation + references here to explain why it’s important to study RBD and IgG and their ratio.

Methods

Overall, methods and its relationship to the introduction is somewhat improved since last draft, enabling some evaluation of the statistical methods.

The Study Sample section is much improved especially regarding sample size and how that number was arrived at.

There is still no necessary detail on the method by which many key anthropometric data were collected. E.g. was body fat percentage by caliper? (It seems maybe bioimpedance? according to Figures 1 and 2, but should be in the text). The authors need to go through the paper with the perspective of a reader trying to understand the methods used.

There is still not enough information in the statistical analysis section on your regression analyses. You need to describe each of the 7 models (even if just briefly) more than merely mentioning that there are 7 in 175. You also need to state what you consider your threshold for statistical significance.

125-127: The added explanations of SISCO and what you meant by metabolic risk score are very helpful to the reader.

139-141: Is effective neutralization >1 or <1? From context of your use of “positive anti-RBD”, I guess that it’s >1, but you need to make this explicit for the reader.

143-148: In terms of logical flow of section order, the ethics statement may fit better if it came right after the “study sample” section.

154-158: This is more a set of data measures, rather than statistical methods, and should be moved to the measures section.

164-174: it is not necessary to go into this great of detail about VIF in the methods section. The much better explanation in 200-202 is all that is needed for a reader unfamiliar with VIF to be able to interpret VIF.

Results

196: Table 1: Your measures of positive anti-RBD and metabolic risk score should be in Table 1 as well.

196: Table 1: Food factors show up in Table 2 (as it should), and should show up here in Table 1 as well, as stated in my last round of suggestions. Again, this goes back to the importance of motivating the study well in the Introduction and making explicit your hypotheses. Why was food something you considered, even if it ended up not significant?

Table 2: I appreciate the addition of Table 2, in which you appear to report all results, and not just the significant ones. Table 2 makes the paper much more cohesive.

Table 2: 95% CI would be much more interpretable to a reader than standard errors.

200-202: this is a good added explanation of how a reader can interpret your VIF.

Discussion

Overall, the findings in the discussion section seem consistent with the newly reported results in table 2.

238-263: as mentioned in the last round, these sources should be part of your introduction to help motivate the study, since they would presumably inform the hypotheses that you’re testing.

259: meta-analysis should not be capitalized.

265: your study is on sex differences, not gender differences.

Reviewer #5: Title: Influence of Adiposity and Sex on SARS-CoV-2 Antibody Response in Vaccinated

University Students: A Cross-Sectional ESFUERSO study.

Abstract

OK

Introduction

Lines 95-98: This section is okay but should be part of the methodology rather than introduction.

Lines 103-105: This paragraph gives a good aim of the study. Please explain why you insist on the border between US and Mexico. Do you have a specific scientific reason why this region was selected for your study. In addition, please add specific research questions just after the aim.

I would suggest that authors add a single paragraph explaining the rationale for this study (why is it important).

Methods

Line 113: “a subset of 116 students was contacted…” => better to write “a subset of 116 students were contacted…”.

Lines 113-116: A total of 116 students contacted but 108 gave blood samples. What happened to the remaining 8 students? Did they decline to give consent for study? Please clarify.

Is it the same number (108) that attended the survey questionnaire? Or 116? If the study targeted 500 participants and only 108 were included, did the authors check if this figure sufficient to allow them extrapolate their findings?

Part of the explanations of sample size are interesting to be included in the manuscript.

Line 142: It is important that authors add a brief paragraph about study design. It is seen that is clinical and prospective study using both survey and lab tests. It is better that this is written in the manuscript; people should not guess. Add also here information about GCP and safety as explained in the answer to reviewer (it should be in the manuscript).

Can authors add a paragraph showing the univariate and bivariate analysis. The answers to reviewers have good information than the manuscript itself.

Ethics

Line 143-148: Please add more details here on the fact that participants got sufficient explanation about benefits and risks for the study and they were free to withdraw from the study any time.

Add a title of “Data presentation” under which you explain how your data are presented in this manuscript: graphs (bar chart, trend lines, pie chart, …), table, text, etc.

Results

I have difficult to understand the way results are presented. I leave this to another reviewer.

Discussion

Very good discussion. However, we don’t see statistical test support the statements (CI, p value, etc.).

Conclusion

Line 276: Can you write conclusion as a title as you did for Introduction, Methods, Results, and Discussion?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Reviewer #5: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS GPH Re-review for Perales-Torres et al. April 2024.docx

pgph.0002686.s005.docx (16.6KB, docx)
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002686.r005

Decision Letter 2

Abram L Wagner

5 Jul 2024

Influence of Adiposity and Sex on SARS-CoV-2 Antibody Response in Vaccinated University Students: A Cross-Sectional ESFUERSO study .

PGPH-D-23-02208R2

Dear Dr. Lopez-Alvarenga,

We are pleased to inform you that your manuscript 'Influence of Adiposity and Sex on SARS-CoV-2 Antibody Response in Vaccinated University Students: A Cross-Sectional ESFUERSO study .' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Abram L. Wagner, PhD, MPH

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

Reviewer #5: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #3: Yes

Reviewer #5: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: This version is greatly improved, the authors are to be commended. All major issues have been addressed. Here are my remaining minor comments:

113-116 does not follow very well from the pervious sentence. The sentence would work better immediately following the sentence in line 99 instead.

218: The sentence is a little awkwardly constructed.

Reviewer #5: Title:

Influence of Adiposity and Sex on SARS-CoV-2 Antibody Response in Vaccinated

University Students: A Cross-Sectional ESFUERSO study.

Abstract

OK

Introduction

OK

Methods

Lines 113-116: A total of 116 students contacted but 108 gave blood samples. What happened to the remaining 8 students? Did they decline to give consent for study? Please clarify.

Is it the same number (108) that attended the survey questionnaire? Or 116? If the study targeted 500 participants and only 108 were included, did the authors check if this figure is sufficient to allow them to extrapolate their findings?

� I did not find answers to the above comments. Maybe I am not able to understand it. So, I leave it to other reviewers.

Ethics

Line 143-148: Please add more details here on the fact that participants got sufficient explanation about benefits and risks for the study, and they were free to withdraw from the study any time.

� I did not see this in the manuscript. Maybe it is not relevant. So, I leave it to other reviewers.

Results

I have difficult to understand the way results are presented. So, I leave this to another reviewer.

Discussion

OK

Conclusion

Line 276: Can you write conclusion as a title as you did for Introduction, Methods, Results, and Discussion?

� This was not addressed. Maybe it is not relevant. So, I leave it other reviewers.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #5: No

**********

Attachment

Submitted filename: Peer review comments from Mateus_Art5_R3.docx

pgph.0002686.s007.docx (18.3KB, docx)

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. Inclusivity in global research.

    (DOCX)

    pgph.0002686.s001.docx (66.1KB, docx)
    S1 Data. Dataset.

    (XLSX)

    pgph.0002686.s002.xlsx (33.3KB, xlsx)
    Attachment

    Submitted filename: Peer review comments from Mateus_Art5.docx

    pgph.0002686.s003.docx (21.9KB, docx)
    Attachment

    Submitted filename: Answer to Reviewer comments v09.docx

    pgph.0002686.s004.docx (45.6KB, docx)
    Attachment

    Submitted filename: PLOS GPH Re-review for Perales-Torres et al. April 2024.docx

    pgph.0002686.s005.docx (16.6KB, docx)
    Attachment

    Submitted filename: 240613_Response to Reviewers.docx

    pgph.0002686.s006.docx (22.5KB, docx)
    Attachment

    Submitted filename: Peer review comments from Mateus_Art5_R3.docx

    pgph.0002686.s007.docx (18.3KB, docx)

    Data Availability Statement

    The dataset is available at https://scholarworks.utrgv.edu/cgi/ir_submit.cgi?context=som_pub.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES